The European Patent Office declared a patent owned by CureVac valid, after a challenge from drugmaker BioNTech, the company said on Thursday. U.S.-listed shares of Germany-based CureVac rose 11.8% in ...

Shares of CureVac (NASDAQ: CVAC) climbed 11% following a favorable patent validity decision in its legal proceedings against BioNTech (NASDAQ: NASDAQ: BNTX). The ...

CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Receives Positive Validity Decision from European Patent Office in Litigation Against BioNTech SE European Patent ...

The U.S. Department of Health and Human Services has reportedly cancelled about $12 billion in federal grants to states ...

The general mood among these heavyweight investors is divided, with 25% leaning bullish and 62% bearish. Among these notable ...

Pfizer (PFE) stock drops as company faces a federal probe on claims of delaying 2020 Covid vaccine success announcement for ...

The U.S. is planning to end its financial support for Gavi, a WHO-backed organization that aims to ensure equitable access to vaccines worldwide, The New York Times reported Wednesday, citing a memo ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of ...

We recently compiled a list of the 12 Most Promising Biotech Stocks According to Wall Street Analysts. In this article, we ...

Goldman Sachs analyst Chris Shibutani maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $136.00.

Autolus Therapeutics PLC (AUTL) reports significant cash reserves and strategic advancements despite increased operational expenses.